Pd 1 Armored(Pd 1 装甲)研究综述
Pd 1 Armored Pd 1 装甲 - This is the first clinical study to evaluate the dominant-negative PD-1 armored anti-CD19 CAR-T-cell. [1] Highlights • This is the first study of dominant-negative PD-1 armored anti-CD19 CAR t cells on refractory b cell lymphoma, demonstrated that the modified CAR t cells were safe and tolerable without extra toxicity. [2]这是第一个评估显性阴性 PD-1 装甲抗 CD19 CAR-T 细胞的临床研究。 [1] 亮点 • 这是针对难治性 b 细胞淋巴瘤的显性阴性 PD-1 装甲抗 CD19 CAR t 细胞的首次研究,证明修饰的 CAR t 细胞是安全且可耐受的,没有额外的毒性。 [2]